SAN CLEMENTE, Calif., Dec. 4, 2008 (GLOBE NEWSWIRE) -- ImmunoBiotics, Inc. (OTCBB:IMBI), a nutraceutical company focused on the discovery and development of safe and effective natural products in the areas of autoimmune, neurological, and metabolic disorders, announced that Thomas P. Lahey, Chairman and CEO of ImmunoBiotics, presented an overview of the Company at the National Investment Banking Association (www.nibanet.org) Capital Conference at 10:25 AM PST on December 4, 2008. The event was held at the Wynn Resort in Las Vegas, Nevada.
About ImmunoBiotics, Inc.
ImmunoBiotics, Inc., a nutraceutical company focused on the discovery and development of safe and effective treatments for autoimmune, neurological, and metabolic diseases, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of immune activation and neuro-inflammation to design dietary supplements derived from botanical sources which have novel mechanisms of action. Based on the results of early-stage clinical trials, ImmunoBiotics believes they have discovered new classes of drug candidates with the potential to be leaders in their markets. ImmunoBiotics is headquartered in San Clemente, California and is traded on the OTC Bulletin Board under the symbol "IMBI." For more information about ImmunoBiotics and its products, visit www.lutimax.com and www.luteolin.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of ImmunoBiotics, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions, regarding our belief that we have discovered classes of new drug candidates with potential to be leaders in their markets. Such forward-looking statements involve known and unknown risks and uncertainties, including statements uncertainties relating to product development and product acceptance, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. ImmunoBiotics, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.